Hoe verhoudt 2500's PS Ratio zich tot zijn concurrenten?

2500 is duur op basis van de Price-To-Sales -ratio ( 5 x) vergeleken met het gemiddelde van de peer ( 4.2 x).

Hoe verhoudt 2500's PS Ratio zich tot andere bedrijven in de HK Medical Equipment industrie?

2500 is duur op basis van de Price-To-Sales -ratio ( 5 x) vergeleken met het Hong Kong Medical Equipment -industriegemiddelde ( 3.2 x).

Wat is 2500's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

2500 is een goede waarde op basis van de Price-To-Sales -ratio ( 5 x) vergeleken met de geschatte eerlijke Price-To-Sales -ratio ( 7.7 x).

Wat is de reële prijs van 2500 als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

2500 ( HK$5.62 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( HK$7.34 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Venus Medtech (Hangzhou) (SZSC:2500) - Aandelenkoers, Nieuws & Analyse

2500 Overzicht aandelen

Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. Meer informatie

2500 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 23.4% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 31.93% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Venus Medtech (Hangzhou) Inc. Concurrenten

Acotec Scientific Holdings

SEHK:6669

HK$2.1b

Modern Dental Group

SEHK:3600

HK$3.6b

Sisram Medical

SEHK:1696

HK$1.6b

MicroTech Medical (Hangzhou)

SEHK:2235

HK$2.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Venus Medtech (Hangzhou)
Historische aandelenkoersen
Huidige aandelenkoers	HK$5.62
52 Week Hoogtepunt	HK$14.94
52 Week Laag	HK$3.74
Bèta	0.55
11 maand verandering	0%
3 maanden verandering	-0.71%
1 Jaar Verandering	-61.61%
33 jaar verandering	-92.66%
5 jaar verandering	n/a
Verandering sinds IPO	-92.89%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	2500	HK Medical Equipment	HK Markt
7D	0%	-0.5%	-2.1%
1Y	-61.6%	-36.7%	11.5%

Rendement versus industrie: 2500 presteerde slechter dan de Hong Kong Medical Equipment -sector, die het afgelopen jaar een rendement van -36.7 % opleverde.

Rendement versus markt: 2500 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 11.5 % opleverde.

Prijsvolatiliteit

Is 2500's price volatile compared to industry and market?
2500 volatility
2500 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	10.0%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.1%
10% least volatile stocks in HK Market	4.2%

Stabiele aandelenkoers: 2500 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 2500 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	1,006	Lin Haosheng Lim	www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Venus Medtech (Hangzhou) zich tot de beurswaarde?
2500 fundamentele statistieken
Marktkapitalisatie	HK$2.46b
Inkomsten(TTM)	-HK$1.31b
Inkomsten(TTM)	HK$491.35m

5.0x

P/S-verhouding

-1.9x

Koers/Winstverhouding

Is 2500 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2500 resultatenrekening (TTM)
Inkomsten	CN¥452.11m
Kosten van inkomsten	CN¥101.03m
Brutowinst	CN¥351.07m
Overige uitgaven	CN¥1.56b
Inkomsten	-CN¥1.21b

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.76
Brutomarge	77.65%
Nettowinstmarge	-267.18%
Schuld/Eigen Vermogen Verhouding	23.4%

Hoe presteerde 2500 op de lange termijn?

Bekijk historische prestaties en vergelijking

2500 Overzicht aandelen

Beloningen

Risicoanalyse

Venus Medtech (Hangzhou) Inc. Concurrenten

SEHK:6669

HK$2.1b

SEHK:3600

HK$3.6b

SEHK:1696

HK$1.6b

SEHK:2235

HK$2.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

No longer forecast to breakeven

New minor risk - Profitability

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

First half 2022 earnings released: CN¥0.46 loss per share (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

No longer forecast to breakeven

Forecast breakeven date pushed back to 2023

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Forecast to breakeven in 2022

Forecast to breakeven in 2022

First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020)

Forecast to breakeven in 2022

GM & Executive Director recently bought HK$35m worth of stock

GM & Executive Director recently bought HK$6.0m worth of stock

GM & Executive Director recently bought HK$30m worth of stock

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2020 Results on Mar 31, 2021

Venus Medtech (Hangzhou) Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.444843 billion.

GM & Executive Director recently sold HK$304m worth of stock

Venus Medtech (Hangzhou) Inc. Announces its CEP Device, TriGUARD3, Completes its First Clinical Application in the PRC

Venus Medtech (Hangzhou) Inc. Announces Change of Joint Company Secretary

COO, CTO & Executive Director recently sold HK$280m worth of stock

COO, CTO & Executive Director recently sold HK$193m worth of stock